PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33472404-0	2021	Identification of Celastrol As a Novel Therapeutic Agent for Pulmonary Arterial Hypertension and Right Ventricular Failure Through Suppression of Bsg (Basigin)/CyPA (Cyclophilin A).	celastrol	18-27	peptidylprolyl isomerase A	Mus musculus	160-164	
33472404-0	2021	Identification of Celastrol As a Novel Therapeutic Agent for Pulmonary Arterial Hypertension and Right Ventricular Failure Through Suppression of Bsg (Basigin)/CyPA (Cyclophilin A).	celastrol	18-27	peptidylprolyl isomerase A	Mus musculus	166-179	
33472404-8	2021	Treatment with celastrol, which we identified as a suppressor of Bsg and CyPA by drug screening, decreased proliferation, reactive oxygen species, and inflammatory cytokines in pulmonary artery smooth muscle cells.	celastrol	15-24	peptidylprolyl isomerase A	Mus musculus	73-77	
29987023-8	2018	Finally, high-throughput screening demonstrated that celastrol, an antioxidant and antiinflammatory agent, reduced the expressions of CyPA and Bsg in the heart and the lung, ameliorating cardiac dysfunction and postcapillary PH induced by TAC.	celastrol	53-62	peptidylprolyl isomerase A	Mus musculus	134-138	
29987023-9	2018	Thus, by differentially affecting CyPA and Bsg expressions, ROCK1 protects and ROCK2 jeopardizes the heart from pressure-overload HF with postcapillary PH, for which celastrol may be a promising agent.	celastrol	166-175	peptidylprolyl isomerase A	Mus musculus	34-38